濮阳东方医院割包皮评价非常高濮阳东方看男科病收费不贵,濮阳东方医院评价很高,濮阳东方妇科医院价格比较低,濮阳市东方医院在线预约,濮阳市东方医院可靠,濮阳东方医院割包皮口碑怎么样,濮阳东方医院男科上班时间

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

When United Flight 93 crashed in Shanksville, PA, on Sept. 11, 2001, John Gerula was one of the first on the scene as a volunteer firefighter. The experience inspired John, still in high school, to enlist in the Marines. He shipped out to Iraq two years later, and today he bears the invisible wounds of war.Over the course of 18 months in Fallujah and Operation Phantom Fury, Gerula survived 21 improvised explosive device blasts, resulting in a severe traumatic brain injury that gave him migraines and memory loss, and post-traumatic stress that left him anxious, isolated and abusing alcohol.“I would spend a lot of time by myself at home on my property, just away from people,” Gerula says. “I didn't like large crowds, just the things that brought me back to what caused my issues, the flashbacks and everything.”That all changed this summer when Oliver, Gerula’s service dog, came into his life.”He can sense when I start to breathe heavy, when my heart rate's high, things of that nature, he comes up to me allows me to pet him,” Gerula says. “Since I’ve had Oliver, I’ve not had a drop of alcohol. I gave up drinking altogether. So he has made huge changes in my life.”Gerula and Oliver are among the first four pairs of veterans and service dogs to graduate from American Humane’s “Shelter to Service” program, created to combat the staggering statistics of 20 veterans committing suicide daily due to PTSD and TBI, and the 670,000 dogs euthanized every year in America’s animal shelters.“We saw a great opportunity to uplift the healing power of the human-animal bond by taking incredible dogs who were abandoned, who needed a second chance at life, giving them unbelievable, rigorous training, and then matching them with our veterans, allowing these veterans a chance for healing, hope, compassion, and love,” says American Humane’s President and CEO Robin Ganzert.Ganzert’s organization is currently training its second “Shelter to Service” class while advocating for a bill on Capitol Hill to establish national training standards and speed up the service dog waitlist, which currently runs from 18 to 24 months.And Gerula has a message to veterans seeking the help with their own struggles.“Don't give up,” he says. “The best thing to do is to keep going and just go do every option you can.” 2346

When a young sperm whale washed up on a beach in southern Spain, scientists wanted to know what killed it. They now know: waste -- 64 pounds of it. Most of it plastic, but also ropes, pieces of net and other debris lodged in its stomach.The discovery has prompted authorities in Murcia, Spain, to launch a campaign to clean up its beaches."The presence of plastic in the ocean and oceans is one of the greatest threats to the conservation of wildlife throughout the world, as many animals are trapped in the trash or ingest large quantities of plastics that end up causing their death," Murcia's general director of environment, Consuelo Rosauro said in a statement.A sperm whale's diet is usually comprised of giant squid. But the 33-foot long mammal that washed up on the beach of Cabo de Palos on February 27 was unusually thin. 839

WEST SENECA, N.Y. —From the running water to the statues and perfectly trimmed plants, Pam and Dave Hubert's backyard in West Seneca, New York, is a place the couple can sit back and relax.But last fall was anything but relaxing for the family."I had a lump in the right side of my throat that I've had many times from having sinus infections," explained Dave. "I went to the doctor and he said something's not right this time.""His words were: you have cancer," Dave said. "You're going to go through hell, but you're going to survive."Dave was diagnosed with throat cancer at the end of August. He had 35 radiation treatments and two rounds of chemo. After months of grueling recovery, he was cancer-free, and could finally sleep and eat again.Pam was by his side throughout it all."We said there's got to be other purpose here than us being sick," Dave said. "I didn't get sick to get sick. I got sick cause someone else needs us to help them get through this."As fall approached this year, Dave had one question for his wife."He said to me, 'do you plan on decorating the yard for the fall?'" Pam recalled. "And I said 'yeah I usually do.' And he said, 'I was hoping you would say that, because last year I just couldn't, I was too tired, too weak I just didn't enjoy it the way I wanted to enjoy it.'""I tried to be out here doing some work," Dave said. "But I was just so tired. I was just so exhausted from the treatment."Pam decided this year needed to be different, so she put out a call on Facebook to people she knew, and to strangers."If there's somebody you know battling cancer or survived cancer, or may have lost a battle to cancer, I would like to honor them," Pam said. "And if you have a pumpkin I'm happy to put it in my yard and we'll display it."That's when the pumpkins started showing up. They have names of patients who have fought cancer, and also messages to those who were lost to the disease. 1929

When it comes to the classroom, it's not unusual for teachers to have assistants. But those helpers aren't always people. At one school, students are learning in a completely new way.We all know it can be fun to play with a dog. But by helping Buster get through an obstacle course, Buster's also helping elementary school student Mason Gentry in ways he hadn't planned."Definitely with focus," Gentry said. "Because sometimes I just have a hard time focusing."But how?"Because I have to help focus on what Buster is doing in order to do what I need to do with him," Gentry said.Buster is teaching schoolmates Ashton Huffman and Grant Meurer, something else."Patience," Huffman said.And it goes beyond getting Buster through the course."It teaches us that if you were to ask for something you can't just go now now I want it now," Meurer said.Once a week dogs like Buster and Mojo, come to Van Arsdale Elementary School in Colorado to work with students.They lead them through courses they've planned out using commands, which helps them develop their communication and confidence."They will get more confident each week," said Vivan Mulhern, coordinator at HABIC Denver. "They will say it louder and then you just see their skills improving and wanting to learn more so then they can connect science together and they can do things like that."Teacher Denise Gillette started the program after seeing how it impacted a student with autism."Were you surprised after that initial student had such a positive reaction from working with the dog?" Kumasi Aaron, a national reporter with The E.W. Scripps Co., asked."Yeah, I think I was surprised," Gillette said. "It was just so beneficial, just such growth."Now more students are seeing that growth, learning a variety of skills that can be challenging to teach, like patience, confidence and focus."They can work on something through the dog that you wouldn't really want to address directly with them," Gillette said. "Like I think if you put the spotlight on them and say you need to have impulse control then you get a resistance but when it's over we need to teach the dog this and then they see, 'Oh that's a valuable thing.'"Gillette writes personalized books to complement her student's work with the dogs, weaving in the lessons each one is trying to learn."Nobody wants to be told you need this you need that," Gillette said. "But when you're helping the dog get it's like, 'Oh okay now you're the helper and you're not always the student who has a problem.'"So while Coen Stevenson has taught Mojo some pretty cool tricks, Mojo's made it easier for him to learn."It makes me feel better to like do more stuff in class and like work better," Stevenson said.A change in curriculum, adding man's best friend, and much more. 2810